AstraZeneca Pharma India Ltd — Profit & Loss Statement

₹7931.00

-5.75%

AstraZeneca Pharma India Ltd Profit & Loss Statement (Annual)

Metric	2025	2024	2023	2022
Tax Effect Of Unusual Items	-25.14 Cr	4.02 Cr	-9.80 Cr	0.65 Cr
Tax Rate For Calcs	0.26	0.26	0.26	0.26
Normalized EBITDA	294.60 Cr	219.25 Cr	188.76 Cr	98.41 Cr
Total Unusual Items	-96.79 Cr	16.43 Cr	-37.77 Cr	2.53 Cr
Total Unusual Items Excluding Goodwill	-96.79 Cr	16.43 Cr	-37.77 Cr	2.53 Cr
Net Income From Continuing Operation Net Minority Interest	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Reconciled Depreciation	39.99 Cr	14.94 Cr	16.26 Cr	16.95 Cr
Reconciled Cost Of Revenue	963.01 Cr	594.56 Cr	425.26 Cr	357.46 Cr
EBITDA	197.81 Cr	235.68 Cr	150.99 Cr	100.94 Cr
EBIT	157.82 Cr	220.74 Cr	134.73 Cr	83.99 Cr
Net Interest Income	-1.46 Cr	-1.20 Cr	22.49 Cr	10.53 Cr
Interest Expense	1.46 Cr	1.20 Cr	0.63 Cr	0.95 Cr
Interest Income	31.56 Cr	32.57 Cr	23.12 Cr	11.48 Cr
Normalized Income	187.39 Cr	149.42 Cr	127.26 Cr	59.72 Cr
Net Income From Continuing And Discontinued Operation	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Total Expenses	1.50K Cr	1.13K Cr	854.08 Cr	735.95 Cr
Rent Expense Supplemental	1.53 Cr	0.46 Cr	0.00	0.04 Cr
Diluted Average Shares	2.50 Cr	2.50 Cr	2.50 Cr	2.50 Cr
Basic Average Shares	2.50 Cr	2.50 Cr	2.50 Cr	2.50 Cr
Diluted EPS	46.30	64.60	39.70	24.60
Basic EPS	46.30	64.60	39.70	24.60
Diluted NI Availto Com Stockholders	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Net Income Common Stockholders	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Otherunder Preferred Stock Dividend	0.00	0.00	0.00	0.00
Net Income	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Net Income Including Noncontrolling Interests	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Net Income Continuous Operations	115.74 Cr	161.51 Cr	99.29 Cr	61.60 Cr
Tax Provision	40.62 Cr	58.03 Cr	34.81 Cr	21.44 Cr
Pretax Income	156.36 Cr	219.54 Cr	134.10 Cr	83.04 Cr
Other Non Operating Income Expenses	40.63 Cr	34.80 Cr	0.21 Cr	0.46 Cr
Special Income Charges	-96.79 Cr	16.43 Cr	-37.77 Cr	2.53 Cr
Other Special Charges	63.64 Cr	-16.46 Cr	-2.49 Cr	-2.82 Cr
Write Off	0.46 Cr	1.24 Cr	0.03 Cr	0.29 Cr
Restructuring And Mergern Acquisition	33.15 Cr	—	40.23 Cr	—
Net Non Operating Interest Income Expense	-1.46 Cr	-1.20 Cr	22.49 Cr	10.53 Cr
Interest Expense Non Operating	1.46 Cr	1.20 Cr	0.63 Cr	0.95 Cr
Interest Income Non Operating	31.56 Cr	32.57 Cr	23.12 Cr	11.48 Cr
Operating Income	213.98 Cr	169.51 Cr	148.89 Cr	69.65 Cr
Operating Expense	539.30 Cr	531.46 Cr	428.82 Cr	378.49 Cr
Other Operating Expenses	157.00 Cr	189.06 Cr	57.31 Cr	46.30 Cr
Depreciation And Amortization In Income Statement	39.99 Cr	14.94 Cr	16.26 Cr	16.95 Cr
Amortization	1.45 Cr	0.13 Cr	0.00	—
Depreciation Income Statement	38.54 Cr	14.94 Cr	16.26 Cr	16.95 Cr
Selling General And Administration	144.84 Cr	86.01 Cr	96.15 Cr	84.99 Cr
Selling And Marketing Expense	93.90 Cr	86.01 Cr	66.22 Cr	56.99 Cr
General And Administrative Expense	50.94 Cr	42.15 Cr	29.93 Cr	28.00 Cr
Rent And Landing Fees	1.53 Cr	0.46 Cr	0.00	0.04 Cr
Gross Profit	753.28 Cr	700.97 Cr	577.71 Cr	448.14 Cr
Cost Of Revenue	963.01 Cr	594.56 Cr	425.26 Cr	357.46 Cr
Total Revenue	1.72K Cr	1.30K Cr	1.00K Cr	805.60 Cr
Operating Revenue	1.72K Cr	1.30K Cr	1.00K Cr	805.60 Cr

All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.

More on AstraZeneca Pharma India Ltd

Overview Financials PE History Shareholding Quarterly Balance Sheet P&L Cash Flow Pharmaceuticals Stocks Screener

Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.